Tue 20 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Scientific Name | Trade Name | Updated Section | Month |
|---|---|---|---|
| Cabazitaxel | Jevtana | 4.8 Undesirable effects | Mar,2023 |
| Cephalexin | Keflex | 4.4 Special Warnings and Special Precautions for Use | Mar,2023 |
| ASCORBIC ACID,SODIUM ASCORBATE,SODIUM SULFATE,MACROGOL ,POTASSIUM CHLORIDE,SODIUM CHLORIDE | Moviprep | 4.4 Special warnings and precautions for use | Mar, 2026 |
| Marstacimab | HYMPAVZI | 4.8. Undesirable effects | Jun, 2026 |
| Valproate Sodium | Epilim Chrono | 4.2 Posology and Method of Administration 6.6 Special Precautions for Disposal and Handling | Jun, 2026 |
| OLMESARTAN MEDOXOMIL, HYDROCHLOROTHIAZIDE, AMLODIPINE BESILATE | SEVIKAR HCT | 4.4 Special warnings and precautions for use 4.8. Undesirable effects | Jun, 2026 |
| METHYLPHENIDATE | Quillivant XR | 4.2 Posology and method of administration | Jun, 2026 |
| Liraglutide | Victoza | 4.8. Undesirable effects | Jun, 2024 |
| Infliximab | Renflexis | 4.8. Undesirable effects | July, 2026 |
| IPTACOPAN | Fabhalta | 4.5 Interaction with other medicinal products and other forms of interaction | July, 2026 |
Last update date: 04/10/2026 at 10:24 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.